Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on April 10, 2025
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
GlobeNewswire
·
April 10, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the …
Love with Boundaries Publishes New Blog on "How to Love an Addict Without Losing Yourself"
EIN Presswire
·
April 10, 2025
Love With Boundaries announces supportive resources and new programs coming soon. VANCOUVER, BC, CANADA, April 9, 2025 /EINPresswire.com/ -- When someone you love is struggling with addiction, it’s easy to get swept into the chaos—losing sleep, walking …
Avalyn to Participate in Upcoming Investor Conference in April
GlobeNewswire
·
April 10, 2025
CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management will …
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
GlobeNewswire
·
April 10, 2025
– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – – Proceeds to support advancement of ninerafaxstat for the …
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire
·
April 10, 2025
– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a patient survey conducted in partnership with the National …
Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
GlobeNewswire
·
April 10, 2025
Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes …
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
GlobeNewswire
·
April 10, 2025
Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood …
Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China
GlobeNewswire
·
April 10, 2025
FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been …
Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting
GlobeNewswire
·
April 10, 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc. (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today announced that it will host an event and …
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
GlobeNewswire
·
April 10, 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new studies of NUZYRA® …
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
GlobeNewswire
·
April 10, 2025
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website …
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
GlobeNewswire
·
April 10, 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy …
CRB Named Rockwell Automation EPC Partner of the Year
GlobeNewswire
·
April 10, 2025
Kansas City, Missouri, April 10, 2025 (GLOBE NEWSWIRE) -- CRB, a leading provider of engineering, architecture, construction, consulting solutions, and control systems integration is honored to be recognized as the Rockwell Automation Engineering, …
Large Reductions in Suicide Risk, Attempts and Deaths Demonstrated by Three “Real World” Studies in Primary Care
GlobeNewswire
·
April 10, 2025
NORWALK, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The suicide rate in the US was at a more than 80-year high in 2022 with a leveling at this higher rate in the past three years. And a large majority of patients who die by suicide have visited a primary …
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire
·
April 10, 2025
– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “ …
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
GlobeNewswire
·
April 10, 2025
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and …
Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
GlobeNewswire
·
April 10, 2025
RESEARCH TRIANGLE PARK, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics has named Roger Ilagan, PhD as its new Chief Scientific Officer (CSO). Responsible for guiding the biologic drug development of first-in-class wound care technology that …
Keros Therapeutics Announces Review of Strategic Alternatives
GlobeNewswire
·
April 10, 2025
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on …
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
GlobeNewswire
·
April 10, 2025
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and …
Neue Imprivata Studie: Mehr als die Hälfte aller befragten deutschen Unternehmen von Cybervorfällen aus der Lieferkette betroffen
GlobeNewswire
·
April 10, 2025
LANGENFELD, Deutschland, April 10, 2025 (GLOBE NEWSWIRE) -- Eine Studie des Ponemon Institutes gemeinsam mit Imprivata ergab, dass 51 Prozent der befragten deutschen Unternehmen einen Datenverlust oder eine Cyberattacke als Folge eines …